Edition:
United States

Novo Nordisk A/S (NVO)

NVO on New York Consolidated

35.63USD
19 Jan 2017
Change (% chg)

$-0.41 (-1.14%)
Prev Close
$36.04
Open
$35.72
Day's High
$35.83
Day's Low
$35.57
Volume
1,439,250
Avg. Vol
3,856,890
52-wk High
$57.81
52-wk Low
$30.89

Latest Key Developments (Source: Significant Developments)

Novo Nordisk CEO questions if company has the right R&D strategy
Thursday, 1 Sep 2016 05:49am EDT 

Chief Executive Lars Rebien Sorensen, Novo Nordisk A/S : Says pricing environment in the United States is becoming more difficult for pharmaceutical companies . Questions if company has the right research and development strategy in the US . Questions if it make sense to make the fifth generation of insulin analogues Further company coverage: [NOVOb.CO] (Copenhagen newsroom) ((copenhagen.newsroom@thomsonreuters.com; +45 33 96 96 55;)).  Full Article

Caverion delivers project for Novo Nordisk's new insulin production facility
Friday, 5 Aug 2016 03:00am EDT 

Caverion Oyj : Caverion delivers a project for Novo Nordisk's new insulin production facility in Hillerød, Denmark . Facility will produce medicines for treatment of diabetes and obesity . Project started in June 2016 and ends in February 2017 . Contract has a volume of approximately 5.4 million euros ($6.02 million) .Builder is Novo Nordisk A/S Full Article

Novo A/S reports 5 pct passive stake in Nabriva Therapeutics
Friday, 29 Jul 2016 11:56am EDT 

Nabriva Therapeutics Ag : Novo A/S reports 5 pct passive stake in Nabriva Therapeutics as of July 19, 2016 - SEC Filing Source - http://bit.ly/2amiXtD Further company coverage: [NBRV.O] (Bengaluru Newsroom; +1 646 223 8780).  Full Article

Novo A/S, main owner of Novo Nordisk, appoints Kasim Kutay as new CEO
Tuesday, 21 Jun 2016 03:50am EDT 

Novo A/S : Says appoints Kasim Kutay as new CEO from September 1, 2016 . Says Kasim Kutay has a proven track record of leadership and significant healthcare expertise. . Novo A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation and main owner of Novo Nordisk A/S. (Copenhagen newsroom) ((copenhagen.newsroom@thomsonreuters.com; +45 33 96 96 03;)).  Full Article

IDegLira receives 16-0 vote in favor of approval from FDA
Tuesday, 24 May 2016 08:15pm EDT 

Novo Nordisk A/S : Says recommendation for approval was based on data from clinical trials of IDegLira .16-0 vote in favor of approval from FDA advisory committee.  Full Article

IDegLira receives 16-0 vote in favor of approval from FDA
Tuesday, 24 May 2016 07:39pm EDT 

Novo Nordisk A/S : Says recommendation for approval was based on data from clinical trials of IDegLira .16-0 vote in favor of approval from FDA advisory committee.  Full Article

Novo Nordisk A/S announces positive results from semaglutide trial
Thursday, 28 Apr 2016 06:25am EDT 

Novo Nordisk A/S:Says semaglutide significantly reduces the risk of adverse cardiovascular events in Sustain 6 trial.Says trial achieved its primary endpoint of showing non-inferiority of cardiovascular events with semaglutide compared with placebo.Says trial showed a statistically significant reduction in cardiovascular risk.Says safety profile of semaglutide in Sustain 6 was as expected.Says expects to file semaglutide for regulatory review in the United States and the European Union in Q4 2016.  Full Article

Novo Nordisk to invest over EUR 100 mln in production plants in France
Wednesday, 20 Apr 2016 08:00pm EDT 

Novo Nordisk A/S:Plans to invest more than 100 million euros in production plants in Chartres, France.New facilities will be built on Novo Nordisk's existing 31,000 m2 site in Chartres.  Full Article

Novo Nordisk says Victoza reduces glycated haemoglobin more than sitagliptin
Monday, 4 Apr 2016 01:10am EDT 

Novo Nordisk A/S:Says Victoza provided superior HbA1c reductions in adults with type 2 diabetes compared to continued sitagliptin treatment.Says adverse events were more common in Victoza group versus sitagliptin group.There were no reports of severe hypoglycaemia and no reports of confirmed nocturnal hypoglycaemia.  Full Article

Novo Nordisk A/S says trial with Tresiba met primary end-point
Tuesday, 23 Feb 2016 05:01am EST 

Novo Nordisk A/S:Says Tresiba demonstrates significantly lower rate of hypoglycaemia than insulin glargine U100 in blinded phase 3b trial in people with type 1 diabetes.Says ‍trial met primary end-point by demonstrating non-inferiority in rate of severe or blood glucose confirmed symptomatic hypoglycemia of Tresiba compared to insulin glargine​.Says ‍expect to initiate filing of data from switch trials with regulatory authorities in Q3 2016 with aim of updating label for Tresiba.  Full Article